Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC reduced its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 7.1% during the 4th quarter, Holdings Channel reports. The fund owned 28,459 shares of the company’s stock after selling 2,188 shares during the quarter. Rafferty Asset Management LLC’s holdings in Dianthus Therapeutics were worth $620,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Alliancebernstein L.P. raised its stake in shares of Dianthus Therapeutics by 13.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after acquiring an additional 136,633 shares in the last quarter. FMR LLC raised its stake in Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after buying an additional 36,133 shares in the last quarter. Walleye Capital LLC raised its stake in Dianthus Therapeutics by 176.3% in the fourth quarter. Walleye Capital LLC now owns 82,890 shares of the company’s stock valued at $1,807,000 after buying an additional 52,890 shares in the last quarter. TCG Crossover Management LLC acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at $32,735,000. Finally, Barclays PLC raised its stake in Dianthus Therapeutics by 2.6% in the fourth quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after buying an additional 1,082 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

DNTH opened at $18.36 on Friday. The business’s 50-day simple moving average is $19.18 and its 200-day simple moving average is $21.90. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27. The stock has a market capitalization of $590.46 million, a P/E ratio of -7.34 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.81 million. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Guggenheim restated a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Robert W. Baird cut their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $53.00.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.